spacer
home > ebr > Spring 2019
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2019

   
Text
PDF
bullet
Biomarkers and Personalised Medicine
Biomarkers for Rare Diseases

Jewel Biomarkers Can Be Found By Digging in the Right Mine

The future of biomarkers is bursting with potential, and surrogate biomarkers are now making way for the development of diagnostic, therapeutic, and prognostic biomarkers, enthuses Professor Hermann Mascher at pharm-analyt Labor.
 
view
download pdf
Biomarkers: The Promise of Personalised Medicine

The Road to Success

Dr Karen Hills and Professor Ken Smith at PredictImmune revisit the history of biomarkers and draw comparisons to more modern examples, demonstrating how biomarkers have become drivers for a more personalised approach to medicine.
 
view
download pdf
Predicting the Health of Future Generations with High-Resolution NMR

Trusting in Biobanking

Professor Matthias Nauck at University Medicine Greifswald introduces nuclear magnetic resonance spectroscopy as a means to enhance biobanking, ultimately progressing modern research techniques such as genomics and personalised medicine.
 
view
download pdf
bullet
Cell Therapy
Laying the Foundation for Successful Advanced Therapies

Bridging the Gap

It is more important than ever for apheresis centres to keep up with the quickly evolving cell therapy landscape, and particular attention needs to be paid to starting materials, urge Dominic Clarke PhD and Brad N Taylor PhD at HemaCare.
 
view
download pdf
Cell and Gene Therapy Development

Opportunities and Challenges in Cancer Innovations

Following some suggestions that almost all cancer treatments will eventually be based on cell and gene therapy approaches, Dr Ger Brophy at Avantor takes a step back to evaluate their progress and what is needed to reap their full potential.
 
view
download pdf
bullet
Discovery and Development Technology
Making Metabolites

Accessing Difficult-to-Synthesise Metabolites in Drug Development Programmes

Julia Shanu-Wilson at Hypha Discovery reviews case studies where different metabolite types, accessed through biological means, have been utilised and summarises the challenges and solutions met in their provision.
 
view
download pdf
Rewriting Drug Discovery and Development

The Authenticity of Synthetics

The impact of synthetic biology is forecast to be broad, as explained by Evonetix’s Dr Tim Brears who sheds light on its potential to empower drug discovery, with particular regard towards DNA sequencing.
 
view
download pdf
bullet
ATMPs and Immunoncology
Q&A: The Growth of Advanced Therapy Medicinal Products

A New Class of Innovation

eXmoor Pharma Concepts’ Dr Angela Obsorne talks to EBR about the promise of advanced therapy medicinal products and the impact of Brexit on the UK's approach to these.
 
view
download pdf
bullet
Features
Ligand-Receptor Identification Methodologies

Details Matter

Protein-protein interaction technologies can only go so far in detecting extracellular interactions, begging the need for alternative methodologies, express Dr Maria P Pavlou and Dr Paul Helbling at Dualsystems Biotech.
 
view
download pdf
Improving Study Outcomes

eCOA Technology in Vaccine Clinical Trials

Vaccine development can be hindered by the processing of large volumes of manual data. Katie Garner at CRF Bracket demonstrates how integrating electronic clinical outcome assessment can combat the burden.
 
view
download pdf
Measuring the Overall Cost of Clinical Drug Trials in Canada

Pricing Clinical Research in the Canadian Industry

Canadian R&D is gaining momentum as the federal and provincial governments gauge the necessary tools to progress innovation. Dr Dat T Tran and Dr Ilke Akpinar at the Institute of Health Economics and Dr Philip Jacobs at the University of Alberta explore further.
 
view
download pdf
Maturing Approaches for the Production of Viral Vectors

Anticipating Advancements

Antony Hitchcock at Cobra Biologics talks supply and demand following the FDA’s prediction that 40 gene therapy products will be licensed by 2020.
 
view
download pdf
The Manufacturing- Regulatory Continuum

Connecting ERP and RIM Data

Eric Gaussens PhD at ProductLife Group divulges the findings from a recent roundtable debate among industry experts focussed on improved data exchange.
 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India forhigh quality, low   cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India’s pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement